TRIM14 suppressed the progression of NSCLC via hexosamine biosynthesis pathway
Carcinogenesis · 2024
DOI: 10.1093/carcin/bgae005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2024. Verfasst von Sisi Wei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing), Cell Proliferation, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation.
Abstract (Originalsprache)
Tripartite Motif 14 (TRIM14) is an oncoprotein that belongs to the E3 ligase TRIM family, which is involved in the progression of various tumors except for non-small cell lung carcinoma (NSCLC). However, little is currently known regarding the function and related mechanisms of TRIM14 in NSCLC. Here, we found that the TRIM14 protein was downregulated in lung adenocarcinoma tissues compared with the adjacent tissues, which can suppress tumor cell proliferation and migration both in vitro and in vivo. Moreover, TRIM14 can directly bind to glutamine fructose-6-phosphate amidotransferase 1 (GFAT1), which in turn results in the degradation of GFAT1 and reduced O-glycosylation levels. GFAT1 is a key enzyme in the rate-limiting step of the hexosamine biosynthetic pathway (HBP). Replenishment of N-acetyl-d-glucosamine can successfully reverse the inhibitory effect of TRIM14 on the NSCLC cell growth and migration as expected. Collectively, our data revealed that TRIM14 suppressed NSCLC cell proliferation and migration through ubiquitination and degradation of GFAT1, providing a new regulatory role for TRIM14 on HBP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
- The National Engineering Research Center for Bioengineering Drugs and the Technologies, The Institute of Translational Medicine, Jiangxi Medical College, Nanchang University, Nanchang 330031, China.
- Department of Pharmacy, Jiangxi Maternal and Child Health Hospital, Nanchang 330006, China.
- Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
- Department of Otorhinolaryngology Head and Neck Surgery, Jiangxi Otorhinolaryngology Head and Neck Surgery Institute, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
ORCID-Profile: Xuan Huang, Yong Li
Förderung
- National Natural Science Foundation of China
- Jiangxi Provincial Natural Science Foundation
Zitieren
APA
Wei, S., Ai, M., Zhan, Y., Yu, J., Xie, T., Hu, Q., Fang, Y., Huang, X., & Li, Y. (2024). TRIM14 suppressed the progression of NSCLC via hexosamine biosynthesis pathway. Carcinogenesis. https://doi.org/10.1093/carcin/bgae005
Vancouver
Wei S, Ai M, Zhan Y, Yu J, Xie T, Hu Q, et al. TRIM14 suppressed the progression of NSCLC via hexosamine biosynthesis pathway. Carcinogenesis. 2024. doi:10.1093/carcin/bgae005
BibTeX
@article{Wei2024,
author = {Wei, Sisi and Ai, Meiling and Zhan, Yuan and Yu, Jieqing and Xie, Tao and Hu, Qinghua and Fang, Yang and Huang, Xuan and Li, Yong},
title = {TRIM14 suppressed the progression of NSCLC via hexosamine biosynthesis pathway},
journal = {Carcinogenesis},
year = {2024},
doi = {10.1093/carcin/bgae005}
}
EUVIMED